

## Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutinin-neuraminidase proteins

Youn-Jeong Lee<sup>1</sup>, Haan-Woo Sung<sup>2</sup>, Jun-Gu Choi<sup>1</sup>, Eun-Kyoung Lee<sup>1</sup>, Hachung Yoon<sup>1</sup>, Jae-Hong Kim<sup>3</sup>, Chang-Seon Song<sup>4,\*</sup>

<sup>1</sup>National Veterinary Research and Quarantine Service, Anyang 430-824, Korea

<sup>2</sup>School of Veterinary Medicine, Kangwon National University, Chunchon 200-701, Korea

<sup>3</sup>College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea

<sup>4</sup>College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea

Recombinant baculoviruses containing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic velogenic (vv) Newcastle disease virus (NDV) isolate, Kr-005/00, and a lentogenic La Sota strain of the NDV were constructed in an attempt to develop an effective subunit vaccine to the recent epizootic vvNDV. The level of protection was determined by evaluating the clinical signs, mortality, and virus shedding from the oropharynx and cloaca of chickens after a challenge with vvNDV Kr-005/00. The recombinant ND F (rND F) and recombinant HN (rND HN) glycoproteins derived from the velogenic strain provided good protection against the clinical signs and mortality, showing a 0.00 PI value and 100% protection after a booster immunization. On the other hand, the combined rND F + HN glycoprotein derived from the velogenic strain induced complete protection (0.00 PI value and 100% protection) and significantly reduced the amount of virus shedding even after a single immunization. The rND F and rND HN glycoproteins derived from the velogenic strain had a slightly, but not significantly, greater protective effect than the lentogenic strain. These results suggest that the combined rND F + HN glycoprotein derived from vvNDV can be an ideal subunit marker vaccine candidate in chickens in a future ND eradication program.

**Keywords:** Newcastle disease, recombinant protein, subunit vaccine

## Introduction

Newcastle disease (ND) is a highly contagious disease in poultry that is characterized by respiratory, nervous, enteric, and reproductive infections. ND can be divided into five pathotypes in chickens according to the severity of the disease: viscerotropic velogenic, neurotropic velogenic, mesogenic, lentogenic or respiratory, and asymptomatic enteric [2]. ND causes serious economic losses in poultry farms and is one of the most important diseases in the poultry industry.

The ND virus (NDV) is a member of the genus *Avulavirus* and the family *Paramyxoviridae* [13,14]. The viral genome encodes six proteins from the 5' terminus to the 3' terminus: RNA-directed RNA polymerase (L gene), hemagglutinin-neuraminidase (HN gene), fusion (F gene), matrix (M gene), phosphoprotein (P gene), and nucleocapsid (NP) protein [2]. The HN and F glycoprotein on the surface of NDV are important for virus infectivity and pathogenicity, and either of these proteins can induce protective immunity [8,15,20,21,24,30].

A number of live and inactivated ND vaccines are used to control ND. However, for commercially available ND vaccines, serological differentiation between birds naturally infected and vaccinated is impossible using a qualitative assay. To overcome this disadvantage, attempts have been made to develop a recombinant virus expressing either the F or HN glycoprotein of NDV in fowl poxvirus [3,4,7,9,10,24,27,28], vaccinia virus [16], and herpesvirus [6,17-19]. The recombinant ND F (rND F) or recombinant HN (rND HN) glycoproteins provided protective immunity against a NDV challenge. Makkay *et al.* [12] also suggested the possibility of serological differentiation between birds naturally infected with a virulent strain of NDV and those vaccinated with the recombinant subunit

\*Corresponding author

Tel: +82-2-450-3712; Fax: +82-2-455-3712

E-mail: songcs@konkuk.ac.kr

vaccine using rND F or rND HN glycoproteins.

Kamiya *et al.* [8] also reported the protective effects and antibody response of rND F and rND HN derived from the virulent and avirulent NDV strains. They used the D26 and Miyadera strains as avirulent and virulent strains, respectively, to evaluate the protective effects and the rND F glycoprotein derived from the avirulent strain had a lower protective effect.

Here, we expressed the rND F and rND HN glycoproteins derived from the lentogenic La Sota strain and the Korean vvNDV Kr-005/00 strain, respectively, using a recombinant baculovirus. The synergistic effects of the combined rND F and rND HN glycoproteins were also compared. The efficacy of the recombinant baculovirus vaccine was evaluated in more detail by comparing the clinical signs, mortality, and amount of virus shedding from the oropharynx and cloaca of vaccinated chickens after a challenge. The aim of this study was to develop a more effective vaccine to prevent ND and to minimize the amount of virus shedding and spreading after a challenge with vvNDV in vaccinated birds. The combined rND F and rND HN glycoproteins derived from vvNDV were evaluated as subunit marker vaccines that might be used as an effective monitoring tool by differentiating the antibodies produced by natural NDV infections from those produced by vaccination.

## Materials and Methods

### Viruses and cells

The Korean viscerotropic velogenic (vv) NDV Kr-005/00 strain and the lentogenic La Sota strain of NDV were grown in 10-day-old specific pathogen free (SPF) embryonated chicken eggs. The *Autographa californica* nucleopolyhedrovirus (AcNPV) and recombinant baculoviruses were grown and assayed in either *Spodoptera frugiperda* 21 (Sf21) cells or *Trichoplusia ni* High Five (Hi5) cells in Grace's medium (GibcoBRL, USA) supplemented with 10% fetal bovine serum. The virus re-isolation of the challenge virus was performed in

primary chicken embryo fibroblast (CEF) cell cultures.

### Construction of the transfer vectors pBacF and pBacHN

Viral RNA was extracted directly from the infective allantoic fluid using an RNeasy kit (Qiagen, USA) according to the manufacturer's recommendations. Four paired primers were used to amplify the complete coding sequence of the fusion (F) and Hemagglutination-Neuraminidase (HN) genes of the La Sota and Kr-005/00 strains (primer sequences, Table 1).

The purified reverse transcription-polymerase chain reaction products of each gene were cloned into a cloning vector, pCR 2.1 (Invitrogen, USA). To construct the transfer vectors pBacF(V) and pBacHN(V), the F and HN genes of the Kr-005/00 strain were excised by digestion with EcoR I and inserted into the EcoR I site of pBacPAK9 (Clontech, USA). The F gene of the La Sota strain was excised by digestion with Xho I and BamH I, and the HN gene of the La Sota strain was excised by digestion with Not I and BamH I. The excised fragments were repaired with T4 polymerase and inserted into the Sma I site of pBacPAK9. The resulting transfer vectors were pBacF(L) and pBacHN(L). All transfer vectors contained the upstream polyhedron promoter of the inserted gene and the downstream polyadenylation sequences. The orientation of the inserted gene was examined by a restriction enzyme treatment and by sequencing the 5' junction region.

### Transfection and selection of recombinant virus

Sf21 cells were transfected with 0.5 µg of the transfer vector plasmid DNA (four each) and BacPAK6 viral DNA (Bsu36 I digest) using the BacPAK baculovirus expression system (Clontech, USA) according to the manufacturer's instructions. After 72 h incubation at 27°C, the culture supernatants were subjected to a plaque assay to isolate the recombinant viruses. The selected plaque was examined to confirm that the target gene had been inserted into the viral genome using polymerase chain reaction with the Bac1 and Bac2 primers (Clontech, USA). Four recombinant

**Table 1.** Primer sequences

Primer	Gene amplified size (bp)	Primer sequence
F (+) for LaSota	1,701	5' TCCAGGTGCAAGATGGGCTCC 3'
F (-) for LaSota		5' AGGGAAACCTTCGTTTCCTCAT 3'
HN (+) for LaSota	1,795	5' TCAATCATGGACCGCGCCGTT 3'
HN (-) for LaSota		5' CGCAGAAGATAGGTGATACAA 3'
F (+) for Kr-005/00	1,719	5' ACATTCAGGACACAATATGGG 3'
F (-) for Kr-005/00		5' CACAGGCTGCTGTTGGGTAT 3'
HN (+) for Kr-005/00	1,779	5' ACAAGAGTCAATCATGGACCG 3'
HN (-) for Kr-005/00		5' TCGTCTTCCAACCATCCTAT 3'

viruses, rND F induced from vvNDV rNDF(V), rND F from La Sota strain rNDF(L), rND HN from vvNDV rNDHN(V), and rND HN from La Sota rNDHN(L), were prepared using pBacF(V), pBacF(L), pBacHN(V), and pBacHN(L), respectively. Recombinant viruses were stored at 4°C until needed.

### Immunofluorescence assay

An immunofluorescence assay was performed without prior fixation, as described previously [22]. Briefly, the Sf21 cells were infected with the recombinant at an MOI of 5 and incubated at 27°C for 48 h. The unfixed infected cells were washed with phosphate-buffered saline (PBS) and incubated with polyclonal chicken anti-NDV sera or monoclonal antibodies specific to the NDV HN glycoprotein for 1 h at room temperature. After washing with PBS, the cells were incubated with fluorescein isothiocyanate-conjugated anti-chicken or anti-mouse immuno-globulin (Cappel, USA) for 1 h at room temperature. The cells were washed again with PBS and examined for fluorescence.

### Chickens

All chickens were derived from SPF eggs of White Leghorn parents (Lohmann, Germany). The animals were housed and reared in positive-pressure isolators until they were immunized.

### Immunization of chickens and challenge

Sf21 cells infected with recombinant viruses were sonicated with Soniprep 150 (Sanyo, UK) at 18 KHz for 5 min, clarified by centrifugation, mixed thoroughly using an Omnimixer with Montanide Incomplete Seppic Adjuvant (ISA-70; Seppic, France) at a ratio of 3 : 7, and used as antigens for immunization. For vaccination, chickens were inoculated intramuscularly with the Seppic-adjuvanted antigen (detailed doses are described in each Table). Each group of vaccinated and unvaccinated chickens was challenged with the vvNDV Kr-005/00 strain through an intraocular inoculation with an  $10^{5.5}$  EID<sub>50</sub> per bird. vvNDV Kr-005/00 was the representative strain of genotype VII, which is the dominant epizootic genotype in Korea [11]. The chickens were kept under observation for 14 days after infection.

### Protection assay

To examine the protective effect of each recombinant glycoprotein, the SPF chickens were immunized with infected cells containing rNDF(V), rNDF(L), rNDHN(V), or rNDHN(L) and the Seppic-adjuvant. In Experiment 1, fifty-five 5-week-old chickens were divided into 11 groups, in which rNDF(V) and rNDHN(V) were subdivided into 4 groups based on the inoculum dose. Five chickens from each group were housed in separate isolators. All chickens

were immunized twice at 3-week intervals and challenged 3 weeks after the second immunization.

In Experiment 2, 120 3-week-old chickens were divided into 8 groups. Four groups were immunized with  $1 \times 10^6$  cells of the infected lysate with an adjuvant of rNDF(V), rNDF(L), rNDHN(V), or rNDHN(L). Two groups were immunized with a half dose ( $0.5 \times 10^6$  cells) of rNDF(V) and rNDHN(V), and the last group was immunized with the combined rNDF(V) and rNDHN(V)-infected cells. The remaining group was used as the non-immunized control. Fifteen chickens in each group were housed in separated isolators. Three weeks after the first immunization, seven chickens from each group were challenged to evaluate the level of immunity, and the remaining eight chickens were given a booster immunization with the same antigen. Three weeks after the second immunization, the chickens were challenged. The protective effect was evaluated by observing the chickens for any clinical signs and mortality. The re-isolation of the challenge virus was carried out in CEF cells with the oropharyngeal and cloacal swab samples 5 day after the challenge infection. All chickens were sampled at 5 d post infection (dpi) including three dead chickens at 4 dpi, one chicken from the rND F(V) group and two chickens from the control group, after the 1st immunization in Experiment 2 (Table 3). For virus isolation, the swab samples were suspended in 1 ml of cell culture medium with antibiotics. And then the clarified supernatants were titrated for virus infectivity in CEF cells.

### Serological assays

The Hemagglutination inhibition (HI) test was performed as described in the OIE manual of standard diagnostic tests [23]. The level of agglutination was assessed by titling the plates. Only those wells in which the RBCs streamed at the same rate as the control wells were considered to exhibit hemagglutination inhibition. ELISA was performed using the Newcastle disease antibody detection kit (IDEXX Laboratories, USA) according to manufacturer's instructions.

### Statistical analyses

For statistical analyses, the two-tailed Fisher's exact test and the Student's t-test were used for the protective immunity and antibody response, respectively. A *p*-value < 0.05 was considered significant.

### Results

The nucleotide sequence of the 5' junction region of the transfer vector indicated that the plasmid contained the inserted gene in the proper orientation for expression. The target gene inserted in the viral genome as assessed by polymerase chain reaction of the selected recombinant virus plaques (data not shown). The expression of the NDV glycoprotein was confirmed by indirect immunofluorescence

analysis (IFA) using the NDV antiserum or monoclonal antibodies specific to the NDV HN glycoprotein. Using IFA, the expressed glycoproteins were localized to the cell surface of the Sf21 cells infected with the recombinant baculovirus, rNDF(V), rNDF(L), rNDHN(V), and rNDHN(L) (data not shown).

In Experiment 1, chickens inoculated with the crude extracts of Sf21 cells infected with the recombinant baculoviruses exhibited serological responses against NDV according to HI and ELISA (Table 2). The HI and ELISA titers of the first immunized groups were significantly higher than those of the non-immunized control except for the  $10^{4.0}$  dose of rNDHN(V) and rNDF(V) (Table 2). The HI titer of the  $10^{7.0}$  dose of rNDHN(L) was significantly lower than those of the  $10^{7.0}$  ( $p < 0.05$ ),  $10^{6.0}$ , and  $10^{5.0}$  doses ( $p < 0.001$ ) of rNDHN(V) after the first immunization. The  $10^{7.0}$  dose of rNDHN(V) induced a lower HI titer than those of the  $10^{6.0}$  and  $10^{5.0}$  doses, but these differences were not statistically significant ( $p > 0.05$ ). The HI titers after the second immunization were similar. However, the  $10^{7.0}$  dose of rNDHN(L) and the  $10^{4.0}$  dose of rNDHN(V) groups showed significantly higher titers than the first immunization ( $p < 0.01$ ). The ELISA titers of each group after the second immunization were significantly higher than the first immunization (Table 2), showing  $p < 0.01$  in groups given the  $10^{7.0}$  dose of rNDF(L) and the  $10^{6.0}$  and  $10^{5.0}$  doses of rNDF(V), and  $p < 0.05$  in the group given the  $10^{7.0}$  dose of rNDF(V). The protection efficacy of the recombinant glycoprotein was evaluated by a challenge

after the second immunization (Table 2). Of the chickens immunized twice with each recombinant glycoprotein, 80% ( $p < 0.05$ ) or 100% ( $p < 0.01$ ) survived the NDV challenge, whereas all unvaccinated birds died.

In Experiment 2, further protective effects of each recombinant glycoprotein were examined (Tables 3 and 4). Although all the second immunized groups exhibited a similar protective effect as in Experiment 1, a  $10^{6.0}$  dose of the infected cells with the adjuvant was chosen to immunize the chickens based on the serological response and protective effect. The protective efficacy of a single dose of each of the four recombinant glycoproteins, a half dose of the two recombinant glycoproteins derived from vvNDV and the combined half dose of rNDF(V) and rNDHN(V)-infected cells were examined.

Protective efficacy tests were performed after the first and second immunizations (Tables 3 and 4). The individual recombinant glycoproteins did not prevent clinical signs and mortality after the first immunization, except for the single dose of rNDHN(V), which had a protective effect against mortality (Table 3,  $p < 0.01$ ). The groups given the single dose of rNDHN(V) and half dose of rNDHN(V) showed a partial protective effect in terms of the clinical signs, but these were not statistically significant ( $p > 0.05$ ). On the other hand, the group given the two glycoproteins, rNDF + HN(V), showed complete protection against the clinical signs and mortality ( $p < 0.001$ ) following only the first immunization. The combined group did not show complete prevention from virus shedding from the oropharynx and cloaca, but the

**Table 2.** Protective effect and antibody response after immunization with the recombinant baculovirus glycoproteins derived from the lentogenic and velogenic Newcastle disease viruses (Experiment 1)

Antigen immunized Dose (cells/bird)	HI titer ( $\log_2 \pm$ SD)		ELISA titer		Protection after 2nd immunization	
	1st*	2nd†	1st	2nd	Mortality‡	
rND F (L)	$10^7$	0.0	0.0	2,242**	5,421††	0/5 <sup>  </sup>
rND F (V)	$10^7$	0.0	0.0	2,644††	5,861††	0/5 <sup>  </sup>
	$10^6$	0.0	0.0	1,735††	4,297††	0/5 <sup>  </sup>
	$10^5$	0.0	0.0	1,366**	3,100††	1/5 <sup>§</sup>
	$10^4$	0.0	0.0	1,085	2,440**	0/5 <sup>  </sup>
rND HN (L)	$10^7$	$1.0 \pm 0.7^{\ddagger}$	$3.4 \pm 0.9^{\ddagger\ddagger}$	n.d.	n.d.	1/5 <sup>§</sup>
rND HN (V)	$10^7$	$2.4 \pm 1.1^{**}$	$3.4 \pm 0.5^{\ddagger\ddagger}$	n.d.	n.d.	1/5 <sup>§</sup>
	$10^6$	$3.8 \pm 0.8^{\ddagger\ddagger}$	$3.8 \pm 1.0^{\ddagger\ddagger}$	n.d.	n.d.	1/5 <sup>§</sup>
	$10^5$	$3.8 \pm 0.8^{\ddagger\ddagger}$	$3.4 \pm 0.9^{\ddagger\ddagger}$	n.d.	n.d.	1/5 <sup>§</sup>
	$10^4$	0.0	$2.4 \pm 1.1^{**}$	n.d.	n.d.	1/5 <sup>§</sup>
Control	—	0.0	0.0	0	0	5/5

\*3 weeks after the first immunization. †3 weeks after the second immunization. ‡Number died over the number tested. § $p < 0.05$  by Fisher's exact test. || $p < 0.01$  by Fisher's exact test. ¶ $p < 0.05$  by Student's *t*-test. \*\* $p < 0.01$  by Student's *t*-test. †† $p < 0.001$  by Student's *t*-test. n.d.: not done.

**Table 3.** Protective effect in chickens after the 1st immunization with the recombinant baculovirus glycoproteins derived from the lentogenic and velogenic Newcastle disease viruses (Experiment 2)

Antigen immunized	Dose ( $\times 10^6$ cells/bird)	Clinical signs		Mortality		PI <sub>14</sub> <sup>‡</sup>	Virus shedding			
		Sick	MTO*	Dead	MDT <sup>†</sup>		Oropharynx		Cloaca	
							No.	Titer <sup>§</sup>	No.	Titer
rND F (L)	1.0	7/7	4.4	4/7	5.0	1.57	7/7	10 <sup>4.0</sup>	6/7	10 <sup>3.0</sup>
rND F (V)	1.0	7/7	4.1	7/7	5.1	2.00	7/7	10 <sup>4.6</sup>	7/7	10 <sup>3.9</sup>
rND HN (L)	1.0	7/7	4.1	7/7	5.1	2.00	7/7	10 <sup>4.4</sup>	7/7	10 <sup>3.9</sup>
rND HN (V)	1.0	3/7	5.0	1/7 <sup>  </sup>	7.0	0.57	7/7	10 <sup>3.4</sup>	7/7	10 <sup>2.3††</sup>
rND F (V)	0.5	7/7	4.0	7/7	5.0	2.00	7/7	10 <sup>4.6</sup>	7/7	10 <sup>4.0</sup>
rND HN (V)	0.5	3/7	4.3	3/7	5.3	0.86	7/7	10 <sup>3.7</sup>	6/7	10 <sup>2.3**</sup>
rND F+HN (V)	0.5+0.5	0/7 <sup>¶</sup>	-	0/7 <sup>¶</sup>	-	0.00	4/7	10 <sup>1.1††</sup>	6/7	10 <sup>1.6††</sup>
Control	-	7/7	4.0	7/7	5.0	2.00	7/7	10 <sup>4.7</sup>	7/7	10 <sup>4.1</sup>

\*Mean time for the onset of clinical signs or death. <sup>†</sup>Mean death time. <sup>‡</sup>Pathogenicity index: the mean score per bird per observation over a 14 day period when each day the birds were scored 0 if normal, 1 if sick, and 2 if dead. <sup>§</sup>Geometric mean titer (log<sub>10</sub> TCID<sub>50</sub>/0.1 ml). <sup>||</sup> $p < 0.01$  by Fisher's exact test. <sup>¶</sup> $p < 0.001$  by Fisher's exact test. <sup>\*\*</sup> $p < 0.05$  by Student's *t*-test. <sup>††</sup> $p < 0.001$  by Student's *t*-test.

**Table 4.** Protective effect in chickens after the 2nd immunization with the recombinant baculovirus glycoproteins derived from the lentogenic and velogenic Newcastle disease viruses (Experiment 2)

Antigen immunized	Dose ( $\times 10^6$ cells/bird)	Clinical signs		Mortality		PI <sub>14</sub> <sup>‡</sup>	Virus shedding			
		Sick	MTO*	Dead	MDT <sup>†</sup>		Oropharynx		Cloaca	
							No.	Titer <sup>§</sup>	No.	Titer
rND F (L)	1.0	1/8**	7.0	1/8**	8.0	0.25	7/8	10 <sup>2.6††</sup>	7/8	10 <sup>2.4</sup>
rND F (V)	1.0	0/7**	-	0/7**	-	0.00	7/7	10 <sup>2.4††</sup>	5/7	10 <sup>1.6††</sup>
rND HN (L)	1.0	3/8 <sup>  </sup>	5.7	2/8 <sup>¶</sup>	5.0	0.63	7/8	10 <sup>2.4††</sup>	7/8	10 <sup>2.0††</sup>
rND HN (V)	1.0	0/8**	-	0/8**	-	0.00	7/8	10 <sup>2.9</sup>	6/8	10 <sup>1.5‡‡</sup>
rND F (V)	0.5	3/8 <sup>  </sup>	4.3	3/8 <sup>  </sup>	5.0	0.75	8/8	10 <sup>3.8</sup>	8/8	10 <sup>2.6</sup>
rND HN (V)	0.5	0/8**	-	0/8**	-	0.00	7/8	10 <sup>1.8‡‡</sup>	7/8	10 <sup>1.3***</sup>
rND F+HN (V)	0.5+0.5	0/8**	-	0/8**	-	0.00	6/8	10 <sup>1.6***</sup>	5/8	10 <sup>1.1‡‡</sup>
Control	-	8/8	4.4	8/8	5.3	2.00	8/8	10 <sup>4.0</sup>	8/8	10 <sup>3.1</sup>

\*Mean time for the onset of clinical signs or death. <sup>†</sup>Mean death time. <sup>‡</sup>Pathogenicity index: the mean score per bird per observation over a 14 day period when each day the birds were scored 0 if normal, 1 if sick, and 2 if dead. <sup>§</sup>Geometric mean titer (log<sub>10</sub> TCID<sub>50</sub>/0.1 ml). <sup>||</sup> $p < 0.05$  by Fisher's exact test. <sup>¶</sup> $p < 0.01$  by Fisher's exact test. <sup>\*\*</sup> $p < 0.001$  by Fisher's exact test. <sup>††</sup> $p < 0.05$  by Student's *t*-test. <sup>‡‡</sup> $p < 0.01$  by Student's *t*-test. <sup>\*\*\*</sup> $p < 0.001$  by Student's *t*-test.

viral titers of this group were significantly lower ( $p < 0.001$ ) than the non-immunized control group.

Unlike the first immunization, the second immunization with the individual recombinant glycoprotein induced a protective effect against the clinical signs, mortality, and virus shedding with statistical significance (Table 4). The rNDF(L) and rNDHN(L) groups showed some clinical signs and mortality after the challenge, and the protective effects of these groups were significant compared with the control group ( $p < 0.001$ , rNDF(L) group;  $p < 0.05$  and  $p < 0.01$ , rNDHN(L) group). The second immunization of

the combined group, rNDF+HN(V), also induced a complete protective effect in terms of the clinical signs and mortality ( $p < 0.001$ ) but the virus shedding still continued, albeit with the reduced titers, compared with the control group ( $p < 0.001$ , oropharynx;  $p < 0.01$ , cloaca).

## Discussion

The protective effect of individual F and HN glycoproteins of the virulent and avirulent strains of NDV and the synergistic effect of the combined F and HN

glycoprotein were examined by inoculating recombinant baculovirus containing the glycoprotein genes intramuscularly into SPF chickens.

Since 1984, genotype VII of NDV has become the dominant epizootic strain throughout Asia, Europe, and Africa. Recent epizootic strains of NDV in Korea also belong to genotype VII [11]. In this study, the F and HN glycoproteins of vvNDV were used to develop a more efficient subunit vaccine for preventing recent epizootic vvNDV infections.

There are several conflicting reports regarding the effects of the individual NDV glycoproteins. According to Sakaguchi *et al.* [26], vaccination of chickens with the recombinant Marek's disease virus serotype 1 (MDV1) expressing the F protein of lentogenic NDV D26 strain produced solid protection against a challenge. Mori *et al.* [19] reported that a recombinant baculovirus expressing the F protein of NDV D26 induced a protective effect. In contrast, Kamiya *et al.* [8] reported that the chickens immunized with rNDF or rNDHN proteins of the velogenic Miyadera strain (rMF or rMHN), the rNDHN protein of the D26 strain (rDHN), or a equal mixture of rMF and rMHN were completely protected from a subsequent challenge. However, chickens immunized with the rNDF protein of the lentogenic D26 strain (rDF) showed a lower protective efficacy.

In this study, chickens immunized with each recombinant glycoprotein were protected (>80%), after the second immunization, from a subsequent challenge with the lethal dose ( $10^{5.5}$  EID<sub>50</sub>/bird) of the recent epizootic strain of vvNDV in Korea (Experiment 1). The chickens immunized with the recombinant fusion glycoprotein derived from the lentogenic La Sota strain, rNDF(L), and from vvNDV and rNDF(V), were also protected from a subsequent challenge. However, the ELISA titers of rNDF(L) were slightly lower than those of the rNDF(V) of the velogenic strain even though the difference was not statistically significant ( $p > 0.05$ ). The HI titers of the rNDHN protein of the lentogenic strain, rND HN(L), were significantly lower than those of rND HN(V) of the velogenic strain after the first immunization ( $p < 0.05$ ).

The efficacy of the individual glycoprotein and the combined F and HN glycoproteins were investigated further (Experiment 2). The individual recombinant glycoproteins did not have a protective effect after the first immunization, even though the rNDHN(V)-immunized group appeared to be protected against mortality ( $p < 0.01$ ). On the other hand, the combined inoculation of the two glycoproteins, rNDF+HN(V), produced complete protection against the clinical signs and mortality ( $p < 0.001$ ) after only a single inoculation. Thus, the combined inoculation of the F and HN glycoproteins had a synergistic effect against a subsequent NDV challenge. Kamiya *et al.* [8] reported that chickens immunized with a

mixture of rMF and rMHN developed a similar level of specific antibodies and protective efficacy compared with the chickens immunized with the individual glycoproteins. In this study, a synergistic effect of the combined inoculation of the F and HN glycoproteins was not detected after the second immunization, as reported by Kamiya *et al.* [8], even though it could be recognized after the first inoculation, in which the individual glycoproteins rarely induced a protective effect. Also, a single inoculation of the combined recombinant glycoprotein was sufficient to induce a protective effect, whereas the individual rND protein needed a booster immunization to induce protection.

Booster immunization of the individual recombinant glycoproteins of vvNDV greatly increased their protective efficacy. However, the rNDF and rNDHN proteins of the lentogenic strain had a slightly lower protective efficacy in the clinical signs and mortality even after the booster immunization, although this difference was not statistically significant (Experiments 1 and 2).

Newcastle disease vaccinations generally protect birds from the more serious consequences of the disease but virus replication and shedding still occur in the infected birds after vaccination, albeit at reduced levels [2]. In this study, chickens immunized with the recombinant glycoprotein were protected against the clinical signs and mortality but virus shedding still occurred, as described in previous studies using live and inactivated vaccines [1,5,25,29,31,32]. Vaccination with the recombinant glycoprotein did not completely inhibit virus shedding from the oropharynx and cloaca but the viral titer was significantly lower than in the non-immunized control group.

This study evaluated the protective effect of individual recombinant glycoproteins derived from velogenic and lentogenic NDV strains. The recombinant glycoproteins from the virulent strain produced complete protection after the second immunization, whereas those from the lentogenic strain had a slightly lower protective effect. Thus, there is a synergistic effect of the combined F and HN glycoprotein, and the use of a subunit vaccine composed of the two glycoproteins can offer good protection against NDV. Although virus shedding still occurred after immunization with NDV glycoproteins, the reduced viral titer would be meaningful in the control of vvND outbreaks. A recombinant subunit marker vaccine should be further examined to establish future control and eradication strategies for ND.

## References

1. Alexander DJ. Newcastle disease and other avian paramyxoviruses, and pneumovirus infections. In: Saif YM, Barnes HJ, Fadly AM, Glisson JR, McDougald LR, Swayne

- DE, (eds.). *Disease of Poultry*. 11th ed. pp. 63-99, Iowa State University Press, Ames, 2003.
2. **Alexander DJ, Manvell RJ, Banks J, Collins MS, Parsons G, Cox B, Frost KM, Speidel EC, Ashman S, Aldous EW.** Experimental assessment of the pathogenicity of the Newcastle disease viruses from outbreaks in Great Britain in 1997 for chickens and turkeys and the protection afforded by vaccination. *Avian Pathol* 1999, **28**, 501-511.
  3. **Bournsnel MEG, Green PF, Campbell JIA, Deuter A, Peters RW, Tomley FM, Samson ACR, Chambers P, Emmerson PT, Binns MM.** Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant. *J Gen Virol* 1990, **71**, 621-628.
  4. **Bournsnel MEG, Green PF, Samson ACR, Campbell JIA, Deuter A, Peters RW, Millar NS, Emmerson PT, Binns MM.** A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. *Virology* 1990, **178**, 297-300.
  5. **Ernawati R, Ibrahim AL.** Newcastle disease vaccination in Malaysia: Application of oil emulsion vaccine. *Vet Rec* 1984, **115**, 352-354.
  6. **Heckert RA, Riva J, Cook S, McMillen J, Schwartz RD.** Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-Neuraminidase antigens. *Avian Dis* 1996, **40**, 770-777.
  7. **Iritani Y, Aoyama S, Takigami S, Hayashi Y, Ogawa R, Yanagida N, Saeki S, Kamogawa K.** Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV. *Avian Dis* 1991, **35**, 659-661.
  8. **Kamiya N, Niikura M, Ono M, Kai C, Matsuura Y, Mikami T.** Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: the fusion protein derived from an avirulent strain had lower protective efficacy. *Virus Res* 1994, **32**, 373-379.
  9. **Karaca K, Sharma JM, Winslow BJ, Junker DE, Reddy S, Cochran M, McMillen J.** Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. *Vaccine* 1998, **16**, 1496-1503.
  10. **King DJ.** A comparison of the onset of protection induced by Newcastle disease virus strain B1 and a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge. *Avian Dis* 1999, **43**, 745-755.
  11. **Lee YJ, Sung HW, Choi JG, Kim JH, Song CS.** Molecular epidemiology of Newcastle disease viruses isolated in South Korea using sequencing of the fusion protein cleavage site region and phylogenetic relationships. *Avian Pathol* 2004, **33**, 482-491.
  12. **Makkay AM, Krell PJ, Nagy E.** Antibody detection-based differential ELISA for NDV-infected or vaccinated chickens versus NDV HN-subunit vaccinated chickens. *Vet Microbiol* 1999, **66**, 209-222.
  13. **Mayo MA.** A summary of taxonomic changes recently approved by ICTV. *Arch Virol* 2002, **147**, 1655-1663.
  14. **Mayo MA.** Virus taxonomy - Houston 2002. *Arch Virol* 2002, **147**, 1071-1076.
  15. **Meulemans G, Gonze M, Carlier MC, Petit P, Burny A, Lê Long.** Protective effects of HN and F glycoprotein specific monoclonal antibodies on experimental Newcastle disease. *Avian Pathol* 1986, **15**, 761-768.
  16. **Meulemans G, Letellier C, Gonze M, Carlier MC, Burny A.** Newcastle disease virus F glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live-virus challenge. *Avian Pathol* 1988, **17**, 821-827.
  17. **Morgan RW, Gelb J Jr, Pope CR, Sondermeijer PJA.** Efficacy in chickens of a herpesvirus of turkeys recombinant vaccine containing the fusion gene of Newcastle disease virus: Onset of protection and effect of maternal antibodies. *Avian Dis* 1993, **37**, 1032-1040.
  18. **Morgan RW, Gelb J Jr, Schreurs CS, Lütticken D, Rosenberger JK, Sondermeijer PJA.** Protection of chickens from Newcastle and Marek's Diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein. *Avian Dis* 1992, **36**, 858-870.
  19. **Mori H, Tawara H, Nakazawa H, Sumida M, Matsubara F, Aoyama S, Iritani Y, Hayashi Y, Kamogawa K.** Expression of the Newcastle disease virus (NDV) fusion glycoprotein and vaccination against NDV challenge with a recombinant baculovirus. *Avian Dis* 1994, **38**, 772-777.
  20. **Nagai Y, Klenk HD, Rott R.** Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. *Virology* 1976, **72**, 494-508.
  21. **Nagy É, Krell PJ, Dulac GC, Derbyshire JB.** Vaccination against Newcastle disease with a recombinant baculovirus hemagglutinin-neuraminidase subunit vaccine. *Avian Dis* 1991, **35**, 585-590.
  22. **Niikura M, Matsuura Y, Hattori M, Onuma M, Mikami T.** Characterization of haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed by a recombinant baculovirus. *Virus Res* 1991, **20**, 31-43.
  23. **Office International Des Epizooties (OIE).** Avian influenza. In: *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*. 6th ed. pp. 465-481, OIE, Paris, 2008.
  24. **Ogawa R, Yanagida N, Saeki S, Saito S, Ohkawa S, Gotoh H, Kodama K, Kamogawa K, Sawaguchi K, Iritani Y.** Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses. *Vaccine* 1990, **8**, 486-490.
  25. **Parede L, Young PL.** The pathogenesis of velogenic Newcastle disease virus infection of chickens of different ages and different levels of immunity. *Avian Dis* 1990, **34**, 803-808.
  26. **Sakaguchi M, Nakamura H, Sonoda K, Okamura H, Yokogawa K, Matsuo K, Hira K.** Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1. *Vaccine* 1998, **16**, 472-479.

27. **Taylor J, Christensen L, Gettig R, Goebel J, Bouquet JF, Mickle TR, Paoletti E.** Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. *Avian Dis* 1996, **40**, 173-180.
28. **Taylor J, Edbauer C, Rey-Senelonge A, Bouquet JF, Norton E, Goebel S, Desmettre P, Paoletti E.** Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. *J Virol* 1990, **64**, 1441-1450.
29. **Turner AJ, Spalatin J, Hanson RP.** The occurrence of virus in leukocytes of vaccinated chickens following challenge with virulent Newcastle disease virus. *Avian Dis* 1976, **20**, 375-381.
30. **Umino Y, Kohama T, Sato TA, Sugiura A.** Protective effect of monoclonal antibodies to Newcastle disease virus in passive immunization. *J Gen Virol* 1990, **71**, 1199-1203.
31. **Utterback WW, Schwartz JH.** Epizootiology of velogenic viscerotropic Newcastle disease in southern California, 1971-1973. *J Am Vet Med Assoc* 1973, **163**, 1080-1088.
32. **Winterfield RW, Dhillon AS, Alby LJ.** Vaccination of chickens against Newcastle disease with live and inactivated Newcastle disease virus. *Poult Sci* 1980, **59**, 240-246.